ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS)

CAPS Rating: 4 out of 5

The Company is a biopharmaceutical company exploiting proprietary RNA-based drug discovery technologies to create a new class of drugs to treat important diseases.

Results 1 - 20 of 127 : 1 2 3 4 5 6 7 Next »

Recs

0
Member Avatar pchop12316 (85.46) Submitted: 8/26/2014 11:02:53 AM : Outperform Start Price: $38.90 ISIS Score: +4.80

upward bound in price

Recs

3
Member Avatar MotleyViking (98.52) Submitted: 6/18/2014 7:03:55 PM : Outperform Start Price: $35.55 ISIS Score: +12.48

Deep pipeline, seemingly has a lot of promise/potential with several drugs.Could be a takeover target, though I don't think there is a much of a chance for that. Value for ISIS is all about their pipeline so we'll see what happens going forward.

Recs

1
Member Avatar Turdtwistr (64.97) Submitted: 6/17/2014 10:21:59 AM : Outperform Start Price: $34.62 ISIS Score: +14.62

great pipeline

Recs

1
Member Avatar Gclever88 (68.81) Submitted: 6/13/2014 5:11:55 PM : Outperform Start Price: $33.60 ISIS Score: +18.29

Like the future possibilities of drug in pipeline.

Recs

1
Member Avatar km00nster (< 20) Submitted: 6/13/2014 3:39:23 PM : Outperform Start Price: $30.61 ISIS Score: +28.42

One of the best pipelines in the industry. Should easily surpass 40 by years end.

Recs

0
Member Avatar danablanca (25.79) Submitted: 6/13/2014 11:36:57 AM : Outperform Start Price: $31.58 ISIS Score: +27.07

Recommended by Jim Jubak in May 2014 and encouraged again here as a beat down that will bounce back so...I'm dipping my toe.

Recs

2
Member Avatar RedandBlack (99.16) Submitted: 6/5/2014 10:51:57 PM : Outperform Start Price: $30.58 ISIS Score: +30.29

$3B market cap with $600M+ in cash and ST investments and not burning cash due to partnerships with big pharma. Good pipeline appears to make this a solid outperform.

Recs

1
Member Avatar ice23bear (29.06) Submitted: 6/2/2014 2:07:11 PM : Outperform Start Price: $28.24 ISIS Score: +40.24

Large pipeline one big drug will do it.

Recs

1
Member Avatar monkeykat (66.71) Submitted: 5/23/2014 6:34:33 PM : Outperform Start Price: $29.05 ISIS Score: +35.25

Great pipeline of drugs and excellent work being done with their RNA treatments.

Recs

1
Member Avatar infinitesimal (57.94) Submitted: 5/14/2014 4:24:52 PM : Outperform Start Price: $25.33 ISIS Score: +54.53

the one or the other will come through finally

Recs

1
Member Avatar marsuculix (25.88) Submitted: 5/14/2014 8:02:44 AM : Outperform Start Price: $27.65 ISIS Score: +41.66

Breaking news today May 14, 2014:
Isis Pharmaceuticals (NASDAQ: ISIS) announced today positive data from a Phase 2 study of ISIS-GCGRRx in patients with type 2 diabetes uncontrolled on stable metformin therapy.
Data look promising so far, however it was a On Treatment Protocol...

Recs

1
Member Avatar FTownBryan (44.90) Submitted: 4/12/2014 12:53:56 PM : Outperform Start Price: $49.81 ISIS Score: -29.58

good value on the pullback. time to load up.

Recs

1
Member Avatar TMFInnovator (63.30) Submitted: 4/10/2014 2:56:19 PM : Outperform Start Price: $35.30 ISIS Score: +6.22

Coupling this with my recent CAPS pick of ALNY for RNA interference and antisense/gene silencing.

The treatment of genetic diseases is not only a huge market, but one that would truly improve the world. With multiple products in clinical trials and a strong partnering program, I think ISIS is in a great position to benefit. Outperform.

Recs

0
Member Avatar simplemts (< 20) Submitted: 4/3/2014 2:15:00 PM : Underperform Start Price: $39.19 ISIS Score: +2.45

short-term.

Recs

0
Member Avatar NHWeston102 (76.69) Submitted: 3/12/2014 11:30:25 AM : Outperform Start Price: $50.41 ISIS Score: -26.39

Poised to enter the biotech majors, ISIS has pipeline, partnerships, and profits.

Recs

0
Member Avatar 1russianguy (72.18) Submitted: 2/28/2014 12:45:38 PM : Outperform Start Price: $53.76 ISIS Score: -31.52

BG long from around $23 (June 13').

Recs

0
Member Avatar rule72 (39.64) Submitted: 2/6/2014 11:13:48 AM : Outperform Start Price: $29.87 ISIS Score: +28.14

This stock seen it grow from $8 to now $46.7 there was a report from barron around May of 2013 saying this stock was not worth keeping or buying. Well that was when around $30 now it is at $ 46
came out with a new drug. So even ones that think they know everything can be wrong.

Recs

1
Member Avatar Wildabeast04 (< 20) Submitted: 1/6/2014 2:53:41 PM : Outperform Start Price: $38.79 ISIS Score: -4.76

Huge pipeline of drugs with great space for growth.

Recs

0
Member Avatar MaliLuke (57.41) Submitted: 12/22/2013 5:27:47 AM : Outperform Start Price: $41.25 ISIS Score: -11.22

A transformational opportunity in biotech with 20 products in clinical trials despite flat sales since 2010' means the one substantial blockbuster could be around the corner and provide revenues for its partnerships, which lower the total risks and cash burn-rate since 2007

Recs

1
Member Avatar CatFoodMoney (72.95) Submitted: 12/18/2013 7:38:26 PM : Outperform Start Price: $38.89 ISIS Score: -5.96

I like biotechs.

Featured Broker Partners


Advertisement